Prevalence of genetically defined tumor cells in CD7 as well as CD26 positive and negative circulating T-cell subsets in Sézary syndrome.
For diagnosis and monitoring of Sézary syndrome flow cytometric quantification of CD7- and CD26- T-cells is widely used. Because antigen loss is a characteristic but not disease-specific finding we investigated the significance of this approach. Therefore we analyzed the prevalence of tumor cells in FACS-sorted CD7+/- as well as CD26+/- circulating T-cells applying a clone-specific qualitative and quantitative T-cell receptor PCR. Tumor cells varied considerably in the CD7+ and CD7- cell subset but were largely confined to the CD26- population. We conclude that quantification of CD26- T-cells reflects the tumor cell amount more accurate and should be preferred in the clinical setting.
Steinhoff
Matthias
M
Department of Dermatology and Allergy, Skin Cancer Center Charité, Charité-Universitaetsmedizin Berlin, Charité-Platz 1, 10117 Berlin, Germany. matthias.steinhoff@charite.de
Schöpp
Sebastian
S
Assaf
Chalid
C
Muche
Marcus
M
Beyer
Marc
M
Sterry
Wolfram
W
Lukowsky
Ansgar
A
D000368:Aged; D000369:Aged, 80 and over; D019011:Antigens, CD7 / Q000276:immunology*; D001483:Base Sequence; D017931:DNA Primers; D018819:Dipeptidyl Peptidase 4 / Q000276:immunology*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D012751:Sezary Syndrome / Q000097:blood / Q000276:immunology*; D016176:T-Lymphocyte Subsets
D019011:Antigens, CD7; D017931:DNA Primers; D011948:Receptors, Antigen, T-Cell; D018819:Dipeptidyl Peptidase 4